Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

12,216 total articles

Hydreight: Buy the Compliance Stack as Telemedicine Goes Local

Hydreight: Buy the Compliance Stack as Telemedicine Goes Local

Hydreight Technologies (HYDTF) has built a compliance-first mobile clinical and telemedicine stack that is winning national white-label partners and posting accelerating top-line growth. For traders willing to accept OTC liquidity and execution risk, the setup offers asymmetric upside if revenue momentum and product rollouts continue to convert int…

Dundee: Momentum Near-Term, But Wait for a Pullback Before Buying

Dundee: Momentum Near-Term, But Wait for a Pullback Before Buying

Dundee Corp (DDEJF) has regained bullish technical momentum with rising SMAs, an RSI in the low-60s and a bullish MACD, but liquidity and valuation dynamics argue for patience. This trade idea: wait for a measured pullback to $3.10 to enter a mid-term swing long (45 trading days), with a stop at $2.75 and a target of $4.25. The plan balances upside…

Cadeler (CDLR): Buy the Offshore Installer at a Tactical Discount

Cadeler (CDLR): Buy the Offshore Installer at a Tactical Discount

Cadeler, owner-operator of Windfarm Installation Vessels Pacific Orca and Pacific Osprey, is trading below its recent highs despite improving technicals and a clear addressable market in European offshore wind. The company trades at a market cap of roughly $2.44B with a P/E near 9.8 and a PB of 1.19. For traders willing to tolerate project timing r…

Why Perspective Therapeutics Deserves a Strong Buy: Bamzireotide-Navoxetan Data Reinvigorates a Clear Phase 3 Pathway

Why Perspective Therapeutics Deserves a Strong Buy: Bamzireotide-Navoxetan Data Reinvigorates a Clear Phase 3 Pathway

Perspective Therapeutics looks like a high-conviction clinical-stage opportunity after reinforced data on its lead program, bamzireotide-navoxetan, and a clear plan to advance into Phase 3. The stock offers asymmetric upside for speculators who accept development risk. This piece lays out the investment thesis, why the market should care, valuation…

Netflix Near a Swing-Floor: I’ll Buy the Breakout or a Clean Retrace

Netflix Near a Swing-Floor: I’ll Buy the Breakout or a Clean Retrace

Netflix has retraced roughly 40% from its 2025 highs, but fundamentals and technicals suggest the stock is carving a base. I plan to buy on a clear breakout above $85 or on a measured retrace into support, targeting $110 over the next 11-45 trading days with a $74 stop. This is a medium-risk swing trade that leans on margin durability, cash flow st…

Wildfire-Driven Inventory Duration: A Mid-Term Buy on Magnolia (MGY)

Wildfire-Driven Inventory Duration: A Mid-Term Buy on Magnolia (MGY)

Magnolia Oil & Gas (MGY) looks positioned to benefit from recent wildfire disruption in South Texas that is extending the company's produced-but-uncompleted inventory and pushing realized pricing power into the next quarter. The balance sheet is clean, free cash flow is meaningful, and technicals show constructive momentum. This trade recommends a …

Micron: The 2028 Overhang Is Losing Its Grip — A Tactical Long Setup

Micron: The 2028 Overhang Is Losing Its Grip — A Tactical Long Setup

Micron has rallied sharply in 2026, but the headline risk that memory demand will crater after large OEM procurement commitments in late 2028 looks increasingly priced in. With a $1.05T market cap, robust margins, and $26.2B in free cash flow last reported, the setup favors a long trade that captures continued AI and cloud memory absorption while m…